Navigation Links
Parkinson's Disease Foundation Awards $300,000 in Bridge Funding for Innovative Research Projects
Date:2/19/2009

NEW YORK, Feb. 19 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation (PDF) has awarded $300,000 in emergency bridge funding to four leading Parkinson's disease scientists. The grants will sustain promising investigations that were recently put into jeopardy by the sudden collapse of their primary private funder, The Picower Foundation.

The Picower Foundation, whose endowment was managed by Bernard Madoff, was forced to cease all grantmaking activities as of the end of 2008.

The awards will support four innovative research projects that were affected by this turn of events, with one-time grants of $75,000 each. The lead scientists on these projects, known in the field for their outstanding work in Parkinson's disease, include J. Timothy Greenamyre, M.D., Ph.D., of the University of Pittsburgh School of Medicine, Virginia M.-Y. Lee, Ph.D., of the University of Pennsylvania School of Medicine, David Sulzer, Ph.D., of Columbia University Medical Center and D. James Surmeier, Ph.D., of Northwestern University Feinberg School of Medicine.

Each project is pursuing a novel avenue of research that may shed light on new ways of treating Parkinson's. Dr. Greenamyre, for example, will test several classes of medications already approved by the FDA for diseases other than Parkinson's to observe whether they are effective in improving gastrointestinal motility in Parkinson's. Despite the frequency and debilitating nature of this nonmotor symptom for people living with Parkinson's, there are no drugs designed specifically to address it.

Dr. Lee, along with John Q. Trojanowski, M.D., Ph.D., is focused on drug discovery, targeting the misfolding, or clumping, of a protein called alpha-synuclein. This clumping is believed to contribute to the cell death that leads to Parkinson's. Their team will test a variety of known compoun
'/>"/>

SOURCE Parkinson's Disease Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
4. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
5. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
6. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
7. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
8. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
9. New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
10. Cardiac Disease in Women Remains Untreated for Decades
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
(Date:12/4/2009)... Ill., Dec. 4 Hospira, Inc. (NYSE: ... delivery company, today announced the launch of its next-generation ... (I.V.) medications and solutions, and now offers a complete ... award-winning, environmentally responsible VisIV product. The launch of the ...
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, today ... and Chief Financial Officer. In this role, Mr. ... functions including finance, accounting, IT, IR, administration and human ... senior management team. ,, "One of my key ...
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Toms of Maine Invites Public Participation in 50 States for Good Program 48207 1Toms of Maine Invites Public Participation in 50 States for Good Program 48207 2More Ontario children are getting diagnosed with diabetes 3A ICES study 48205 1Common chemotherapy drug triggers fatal allergic reactions 8748 1Common chemotherapy drug triggers fatal allergic reactions 8748 2Common chemotherapy drug triggers fatal allergic reactions 8748 3
... June 11, 2007 (MARKET WIRE via COMTEX ... (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ),announced today that it ... and a "Randomized Withdrawal" clinical trial,design with ... at the Alzheimer's Association Prevention Conference held,June ...
... /PRNewswire-FirstCall/ - Paul S.,Aisen, M.D., Professor of ... and principal investigator in the United,States of ... trial,for tramiprosate (ALZHEMED(TM)) will present today an ... treatment of,Alzheimer's disease (AD). The presentation by ...
Other Medicine Technology:Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4
(Date:12/7/2009)... NEW ORLEANS, Dec. 7 Cell Therapeutics, ... that Ruth Pettengell, M.D. of St. George,s Hospital, ... 2009 American Society of Hematology ("ASH") Annual Meeting ... (PIX 301) clinical trial of pixantrone (the "PIX ... non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
(Date:12/6/2009)... OAK BROOK, Ill., Dec. 7 The ... center (AMC) members for their achievements in UHC,s ... 10 organizations are noted for modeling best practices ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were ... calculation that includes contract portfolio participation and use ...
(Date:12/6/2009)... discovered that the loss of a key segment of DNA ... study to show that this kind of genetic alteration can ... . , The study, led by Dr Sadaf Farooqi from ... Wellcome Trust Sanger Institute, looked at 300 children with severe ... for types of mutation known as copy number variants (CNVs). ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Onyx Pharmaceuticals, Inc. ... data from the pivotal Phase 2b 003-A1 study, ... is well-tolerated in heavily pre-treated relapsed and refractory ... at the ASH/ASCO Joint Symposium at the 51st ... (ASH) in New Orleans. Enrollment in this trial ...
(Date:12/6/2009)... www.sleeping-with-a-sleeping-disorder.com is asking people ,who have ... aids from around the world to donate their ... submissions will be compiled in an ebook titled ... be sold from the website in early January ... proceeds ,from sales of the E-book to three ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2
... SHENZHEN, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- China Display,Technologies, ... "the,Company"), a leading manufacturer of optoelectronic products, specializing,in ... for LCD displays in,China, today announced its Vice ... Officer, Mr. Kam Ming Yip will present at ...
... of genes that prevent cell death in those with ... Researchers from Saint Louis University report that a pile-up ... finding which could point to new therapies for the ... finding new treatments for lupus," said Dr. Jill Buyon, ...
... nomination campaign, some candidates health care plans have been ... has been used to attack health reform proposals in ... Opinion Research Program at the Harvard School of Public ... split on whether a socialized medical system would be ...
... 14 Workplace stress is the,most frequently cited ... acknowledge that stress is affecting business performance,few are ... surveys by Watson,Wyatt Worldwide, a leading global consulting ... percent) say stress caused by working,long hours is ...
... Officials at,Southern Research Institute today announced that Wilson ... has been named Vice,President of its Drug Discovery ... "We are very pleased that Dr. Knight has ... research program," said John A. "Jack" Secrist,III, Ph.D., ...
... WASHINGTON, Feb. 14 Lung Cancer Alliance,announced today ... joined its Board of Directors., LCA Board ... the,following statement:, "Secretary Mineta,s remarkable career in ... leadership on national security, transportation,infrastructure and technology issues ...
Other Medicine News:Health News:China Display Technologies, Inc. to Present at Roth Conference 2Health News:China Display Technologies, Inc. to Present at Roth Conference 3Health News:Overabundance of Immune Cells Might Trigger Lupus 2Health News:Overabundance of Immune Cells Might Trigger Lupus 3Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find 2Health News:Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find 3Health News:Southern Research Institute Names Blaine Knight Vice President of Drug Discovery 2Health News:Secretary Norman Y. Mineta Joins Lung Cancer Alliance Board of Directors 2
... The Acclaim 7000 Nd:YAG laser ... by offering cosmetic procedures such as ... facial veins, our Dermique LaserFACIAL for ... offers selectable parameters for customizing treatment ...
... laser beam is delivered through an ultra thin ... the operator full freedom of movement when performing ... with a wide range of handpieces. Handpieces ... mm and 16 mm. Straight and angled ...
VERSASTEP™ Reposable Reusable Components (Standard Length)....
VERSASTEP™ Reposable Single Use Trocar For use with VERSASTEP™ Reusable Cannula, Dilator....
Medicine Products: